Johnson & Johnson Forecasts 7.3% EPS Growth, $100B Revenue

Johnson & Johnson raised its growth ambitions, forecasting 6.5% adjusted operational sales growth and 7.3% adjusted EPS growth in 2026, with revenue expected to surpass $100 billion. Despite STELARA biosimilar competition, executives see 2027 improving further and aim for double-digit growth by the end of the decade. The company plans to hold an enterprise business review in early December to discuss the drivers of its goal for double-digit growth and provide additional information on earlier-stage pipeline assets.